Erik Stiles1, Karl C Alcover1, Bryan Stiles2, Oladunni Oluwoye1,3, Michael G McDonell1,3. 1. Elson S. Floyd College of Medicine, Washington State University, Spokane, Washington, USA. 2. Department of Psychology and Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 3. Washington State Center of Excellence in Early Psychosis, Spokane, Washington, USA.
Abstract
AIM: To explore the relationship between cannabis use and metabolic syndrome (MetS) among those who have experienced first episode psychosis (FEP). METHODS: A retrospective analysis of 404 participants enrolled in the Recovery After Initial Schizophrenia Episode-Early Treatment Program (RAISE-ETP) was conducted. Using multiple logistic regression, we investigated the correlation between cannabis use and rate of MetS at baseline and across time as well as the specific metabolic derangements among cannabis users and abstainers. RESULTS: Although cannabis users had similar rates of MetS at baseline when compared with abstainers, those who used cannabis at any time during the study period tended to have lower triglycerides and elevated high-density lipoprotein (HDL). Cannabis users were less likely to develop MetS, relative to nonusers. CONCLUSIONS: Cannabis use may be associated with lower incidence of MetS in patients who have experienced FEP. Further research is indicated to develop these observations.
AIM: To explore the relationship between cannabis use and metabolic syndrome (MetS) among those who have experienced first episode psychosis (FEP). METHODS: A retrospective analysis of 404 participants enrolled in the Recovery After Initial Schizophrenia Episode-Early Treatment Program (RAISE-ETP) was conducted. Using multiple logistic regression, we investigated the correlation between cannabis use and rate of MetS at baseline and across time as well as the specific metabolic derangements among cannabis users and abstainers. RESULTS: Although cannabis users had similar rates of MetS at baseline when compared with abstainers, those who used cannabis at any time during the study period tended to have lower triglycerides and elevated high-density lipoprotein (HDL). Cannabis users were less likely to develop MetS, relative to nonusers. CONCLUSIONS: Cannabis use may be associated with lower incidence of MetS in patients who have experienced FEP. Further research is indicated to develop these observations.
Authors: John M Kane; Nina R Schooler; Patricia Marcy; Christoph U Correll; Mary F Brunette; Kim T Mueser; Robert A Rosenheck; Jean Addington; Sue E Estroff; James Robinson; David L Penn; Delbert G Robinson Journal: J Clin Psychiatry Date: 2015-03 Impact factor: 4.384
Authors: Christoph U Correll; Delbert G Robinson; Nina R Schooler; Mary F Brunette; Kim T Mueser; Robert A Rosenheck; Patricia Marcy; Jean Addington; Sue E Estroff; James Robinson; David L Penn; Susan Azrin; Amy Goldstein; Joanne Severe; Robert Heinssen; John M Kane Journal: JAMA Psychiatry Date: 2014-12-01 Impact factor: 21.596
Authors: Robert Rosenheck; Douglas Leslie; Kyaw Sint; Haiqun Lin; Delbert G Robinson; Nina R Schooler; Kim T Mueser; David L Penn; Jean Addington; Mary F Brunette; Christoph U Correll; Sue E Estroff; Patricia Marcy; James Robinson; Joanne Severe; Agnes Rupp; Michael Schoenbaum; John M Kane Journal: Schizophr Bull Date: 2016-01-31 Impact factor: 9.306
Authors: Yolanda Alonso; Carmen Miralles; M José Algora; Alba Valiente-Pallejà; Vanessa Sánchez-Gistau; Gerard Muntané; Javier Labad; Elisabet Vilella; Lourdes Martorell Journal: Sci Rep Date: 2022-07-06 Impact factor: 4.996